English Deutsch 中文
  • Innovative Solutions
  • Expert Support and Knowledge
  • Reliable Cooperation
Menu Deutsch 中文

Sihuan Granted SFDA Approval to Test New Drugs

Feb. 21, 2013

Sihuan Pharma announced that it had received permission from the SFDA to begin clinical trials of two of its drug-candidates: Pinoxacin Hydrochloride, a Category 1.1 drug for the treatment of Type II Diabetes; and Benapenem, also a Category 1.1 drug, for the treatment of multiple drug resistance (“MDR”). The Beijing-based company said it would start a Phase I trial in both drug-candidates in the first half of 2013.